Quarterly ResultMay 13, 2026, 05:27 PM
Kairos Pharma Q1 Net Loss $(1.65)M; Cash $3.68M
AI Summary
Kairos Pharma, Ltd. reported a net loss of $1.65 million for the three months ended March 31, 2026, an increase from $1.26 million in the prior year. The company had no revenue and its cash and cash equivalents decreased to $3.68 million from $4.49 million at the end of 2025. The filing also highlighted substantial doubt about the company's ability to continue as a going concern, with existing cash potentially insufficient for the next 12 months.
Key Highlights
- Net loss for Q1 2026 was $(1.65) million, compared to $(1.26) million in Q1 2025.
- Cash and cash equivalents stood at $3.68 million as of March 31, 2026, down from $4.49 million at December 31, 2025.
- Operating expenses increased to $1.69 million in Q1 2026 from $1.27 million in Q1 2025.
- Research and development expenses rose to $684 thousand from $493 thousand year-over-year.
- General and administrative expenses increased to $1.01 million from $773 thousand year-over-year.
- Net cash used in operating activities was $(1.04) million in Q1 2026, up from $(714) thousand in Q1 2025.
- Raised gross proceeds of $385 thousand through an At the Market (ATM) offering in Q1 2026.
- Total deferred offering costs were $1.28 million as of March 31, 2026.